jc
@JadChahoud
Followers
788
Following
9K
Media
3
Statuses
3K
Genitourinary Medical Oncologist @MoffittNews @MoffittResearch
Joined April 2012
RT @ConquerCancerFd: Dr. Ohlsen describes what it’s like to be an early-career researcher looking for support in today’s funding landscape.….
0
1
0
RT @SpiessPhilippe: Societie International d'Urologie (SIU) is a urological society with more than 17,000 members from over 130 countries g….
0
5
0
RT @claudebassil: Honored to lead and participate with Dr. Spiess in our newest manuscript : Management and optimization of chronic renal….
pubmed.ncbi.nlm.nih.gov
Our investigation into the intricate relationship between chronic kidney disease and renal cell carcinoma has many multifaceted challenges for both patients and healthcare providers face. This...
0
4
0
RT @IKCCorg: 📣 Open Call: There is one IKCC Board position open for nomination for 2025: General Board Director. Deadline for applications….
0
1
0
RT @hsafaMD: 🚨 Fellowship Applicants 🚨. Visibility matters. Believe it or not, people have landed interviews by having a presence on X. Dr….
0
14
0
RT @hsafaMD: The best part of Hematology/Oncology?.You build deep, meaningful relationships with your patients. The hardest part of Hemato….
0
12
0
@NEJM INAVO120 Trial Highlights in PIK3CA-mutated HR+/HER2- mBC:.✅ OS: 34.0 mo (inavolisib) vs 27.0 mo (placebo).✅ HR for death: 0.67 (P = 0.02).✅ ORR: 62.7% vs 28.0% (P < 0.001).✅ PFS HR: 0.42.⚠️ AEs: More GI, mucosal with inavolisib #bcsm
nejm.org
In the phase 3, double-blind, randomized INAVO120 trial, treatment with inavolisib plus palbociclib–fulvestrant led to a significant progression-free survival benefit, as compared with placebo plus...
0
0
1
RT @HindRafei: Thrilled, honored, and humbled to be selected as a new Sabin fellow @MDAndersonNews! Immensely grateful to the Sabin family….
0
5
0
RT @hsafaMD: Excited to share I’ve been accepted to the 2025 ASCO/AACR Methods in Clinical Cancer Research Workshop in La Jolla, San Diego.….
0
1
0
RT @MyriamChalabi: Very much looking forward to #ESMO25 in the 😎 city of #Berlin! Huge increase in abstract submissions, and the team is cu….
0
13
0
RT @PavlosMsaouel: 1/5 How reproducible are phase III oncology trials?.📊 With @AlexSherryMD @ErikVanZwet @ebludmir et al. We analyzed 632 R….
0
36
0
RT @oncodaily: @hsafaMD We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. .
oncodaily.com
Houssein Safa: Launching a New Series for Interns, Residents, and Hospitalists / cancer, Houssein Safa, OncoDaily, Oncology
0
2
0
RT @hsafaMD: 🚀 Launching a new series for interns, residents, and hospitalists:. 🎗️ Oncology for The Non-Oncologist Tuesdays 🎗️.🩸 Hematolog….
0
4
0
RT @PavlosMsaouel: 1/5 #RenalMedullaryCarcinoma (RMC) is a lethal #KidneyCancer in young people with #SickleCellTrait (SCT). Our new prospe….
0
22
0
RT @GIcancerDoc: @Ahn_Daniel_Onc from @MayoCancerCare presenting positive results for his study with #parp inhibitor Olaparib in #HRR….
0
17
0
RT @MariaJRibal: 10 years ago, under the vision of @NDowJames, we set out to bring #EAUGuidelines to #socialmedia . It started with a small….
0
16
0
RT @AnnaliceGandini: Real-world data on the safety and eficacy of ENCO plus PANI in BRAF V600E mutated mCRC patients who experienced severe….
0
6
0
RT @PavlosMsaouel: 🚀 Now enrolling @MDAndersonNews: IVORY trial of #ivonescimab (first-in-class PD1×VEGF bispecific) in metastatic clear ce….
0
25
0